South Africa antirheumatic drugs market was valued at US$1,028.434 million in 2019. The market in South Africa is projected to grow at a notable CAGR throughout the forecast period. The major factors that drive the antirheumatic drugs market in the country include the high prevalence of rheumatoid arthritis coupled with the intense incidence of malaria throughout the country. According to the data from the World Health Organization, in 2018 the country reported around 9500 indigenous malaria cases which were considerably lesser than in 2017. In 2017, around 22,000 cases were reported in the country. The increased government funding for meeting the response of malaria is also anticipated to positively impact the demand for various types of drugs and thus, drive the market growth during the next five years. Furthermore, the high prevalence of arthritis in the country along with the growing geriatric population is also considered to be the prime factors that are expected to drive growth throughout the forecast period. Also, the less number of rheumatologists is considered to be a major factor for the high prevalence of this disease in the country. There are currently 64 registered rheumatologists in the country, which gives a ratio of around 1 doctor for more than 800,000 inhabitants (Source: South African Rheumatism and Arthritis Association). According to the World Bank Group, the population ages 65 and above increased from 2,433,350 in 2010 to 3,072,723 by 2018.
South Africa antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, the South Africa antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).